BioPorto (BIOPOR) Status Update summary
Event summary combining transcript, slides, and related documents.
Status Update summary
12 Sep, 2025Current state and challenges in kidney care
Acute kidney injury (AKI) and chronic kidney disease (CKD) are rising globally, now reaching epidemic levels and affecting a significant portion of hospitalized patients, with many cases going undiagnosed until late stages.
Advances in critical care have improved survival rates for children and adults with kidney issues, but many survivors live with chronic conditions, increasing the burden on healthcare systems.
There is a severe shortage of nephrologists, especially in pediatrics, making it essential for primary care and other specialists to be involved in early detection and management.
Access to new therapies is limited by cost and insurance coverage, creating disparities in care, particularly in underserved populations.
Care coordination is hampered by resource constraints, especially for non-physician team members critical to comprehensive kidney care.
Innovations and advances in diagnostics and treatment
The NGAL biomarker, developed over 25 years, enables early detection of AKI and is now FDA-cleared for pediatric use, with ongoing trials in adults.
NGAL and other biomarkers help differentiate between functional and structural kidney injury, guide treatment decisions, and are used in drug development for nephrotoxicity assessment.
New medications, including SGLT2 inhibitors, GLP-1 agonists, and MRAs, have expanded treatment options for CKD, but access remains a challenge.
Pediatric innovations like the Carpe Diem dialysis machine have transformed care for infants with severe kidney disease, enabling earlier and safer interventions.
Role of artificial intelligence and data-driven care
AI and machine learning models are being integrated into nephrology to predict AKI risk, optimize dialysis, and analyze complex patient data in real time.
Combining AI-generated risk scores with biomarkers aims to improve prediction accuracy and personalize interventions.
Successful implementation of AI requires collaboration between clinical experts and data scientists, with attention to data quality and cybersecurity.
Latest events from BioPorto
- 2025 revenue up 11% year-over-year, with strong US NGAL growth and key strategic milestones.BIOPOR
Q4 202526 Mar 2026 - 2026 guidance targets 20–50% NGAL growth, expanded US adoption, and improved EBITDA loss.BIOPOR
Guidance27 Feb 2026 - NGAL diagnostics drive rapid AKI detection and global adoption, supported by strong sales and partnerships.BIOPOR
Status Update19 Jan 2026 - Q3 2025 delivered 7% revenue growth, strong US NGAL sales, and DKK 43m in new funding.BIOPOR
Q3 202519 Nov 2025 - Three-year plan targets global kidney biomarker growth, cashflow positivity by 2027, and FDA adult approval.BIOPOR
Status Update6 Nov 2025 - Q2 2025 delivered strong NGAL-driven growth, a widened EBITDA loss, and a narrowed 2025 outlook.BIOPOR
Q2 202515 Aug 2025 - US NGAL sales surged 34% in 2024, fueling growth and supporting ambitious 2029 targets.BIOPOR
AGM 2025 Presentation15 Aug 2025 - 16% revenue growth driven by NGAL sales and global partnerships; 2024 guidance maintained.BIOPOR
Q3 202413 Jun 2025 - H1 2024 revenue up 18%, driven by 43% US NGAL sales growth and strong funding.BIOPOR
Q2 202413 Jun 2025